Vaccine Development

Conjugated CD20 vaccine elicits specific, polyclonal immune response in mice

Published in Blood Weekly, July 18th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - The CD20 antigen, expressed only on B lineage cells before differentiation into plasma cells, produced a strong, specific, polyclonal immune response in mice, researchers in New York have found.

"Monoclonal antibodies to CD20 have been used successfully in the treatment of B-cell lymphomas," explained W.K. Roberts and colleagues at the Memorial Sloan-Kettering Cancer Center in New York City. "Vaccine therapy would have the advantage of generating a polyclonal response to the antigen in contrast to the monoclonal response of an infused antibody."

The investigators inoculated Balb/c mice with a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry